Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a product recall and subsequent stock price drop [1][2]. Group 1: Product Recall and Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses from its enVista platform due to reports of toxic anterior segment syndrome (TASS), which is a complication associated with cataract surgery [2]. - The recall has raised short-term concerns regarding product safety and may lead to increased regulatory scrutiny [2]. - Following the recall announcement, Bausch + Lomb's stock price fell by $1.50 per share, representing a 10.6% decrease, closing at $15.00 on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Bausch + Lomb on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information related to the claims [3].

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Bausch + Lomb and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On March ...